AZ research exec Johnson jumps to Goldfinch, Human Longevity undergoes C-suite earthquake, Biogen poaches Takeda exec as CIO.

Gilead has made a bolt-on acquisition of Cell Design with an eye to the future of CAR-T.

Juno Therapeutics, which dumped its lead CAR-T program in March, has inked license agreements with Eli Lilly, OncoTracker and Fred Hutch.

SAGE-217 triggered near-immediate, fairly durable improvements in patients with major depressive disorder.

Officials want firms to team up to test multiple candidates in single trials, thereby cutting the number of patients who receive placebos.

Metacrine is adding to this week's NASH talk after getting off a series B as it aims to combat the fatty liver disorder.

Boosting the hedgehog signaling pathway stopped fat cells from growing in mice fed a high-fat diet.

With the launch of its $44.2 million life sciences venture capital fund, the AmorChem Group now has $86 million under management.